Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison

详细信息    查看全文

• 作者：Sarah M. Cockle^a ; Gillian Stynes^a ; ¹ ; Necdet B. Gunsoy^b ; Daniel Parks^c ; Rafael Alfonso-Cristancho^c ; Jaro Wex^d ; Eric S. Bradford^e ; Frank C. Albers^e ; Jenny Willson^a ; ^{jenny.x.willson@gsk.com}
• 关键词：Mepolizumab ; Omalizumab ; Severe asthma ; Exacerbations ; Lung function ; Tolerability
• 刊名：Respiratory Medicine
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：123
• 期：Complete
• 页码：140-148
• 全文大小：436 K
• 卷排序：123

文摘

Patients with severe asthma may be eligible for both mepolizumab and omalizumab. Evidence of the relative effectiveness of these treatments would be informative. Treatment effectiveness was examined via an indirect treatment comparison. Exacerbation rates, lung function and tolerability profiles were broadly comparable. Mepolizumab seems to be at least as effective as omalizumab in severe asthma.